IRIS
AGHEMO, Alessio Michele Goffredo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.653
AS - Asia 4.615
EU - Europa 2.057
SA - Sud America 1.316
AF - Africa 356
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 8
Totale 20.020
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.458
SG - Singapore 2.888
BR - Brasile 1.135
CN - Cina 896
FI - Finlandia 441
IE - Irlanda 316
NG - Nigeria 272
IT - Italia 244
DE - Germania 231
VN - Vietnam 199
HK - Hong Kong 185
FR - Francia 163
GB - Regno Unito 134
CA - Canada 129
NL - Olanda 128
SE - Svezia 108
IN - India 86
AR - Argentina 77
RU - Federazione Russa 71
TR - Turchia 66
IL - Israele 48
BD - Bangladesh 43
BE - Belgio 43
MX - Messico 39
UA - Ucraina 29
PL - Polonia 27
EC - Ecuador 26
EG - Egitto 25
ID - Indonesia 25
IQ - Iraq 24
ES - Italia 21
JP - Giappone 20
MK - Macedonia 20
CO - Colombia 19
IR - Iran 19
ZA - Sudafrica 19
UZ - Uzbekistan 18
VE - Venezuela 18
PY - Paraguay 15
PK - Pakistan 14
CZ - Repubblica Ceca 12
AU - Australia 11
KE - Kenya 11
PE - Perù 10
KR - Corea 9
MA - Marocco 9
PH - Filippine 9
RO - Romania 9
AT - Austria 8
JO - Giordania 8
AL - Albania 7
AZ - Azerbaigian 7
LT - Lituania 7
SA - Arabia Saudita 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AE - Emirati Arabi Uniti 6
CH - Svizzera 6
CL - Cile 6
DZ - Algeria 6
GR - Grecia 6
NP - Nepal 6
TN - Tunisia 6
UY - Uruguay 6
JM - Giamaica 5
KZ - Kazakistan 5
OM - Oman 5
BG - Bulgaria 4
PA - Panama 4
RS - Serbia 4
TW - Taiwan 4
DO - Repubblica Dominicana 3
ET - Etiopia 3
HN - Honduras 3
LV - Lettonia 3
MD - Moldavia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BB - Barbados 2
BS - Bahamas 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
NI - Nicaragua 2
PT - Portogallo 2
SR - Suriname 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GD - Grenada 1
Totale 20.005
Salva come PNG Salva come JPEG
Città #
Chandler 1.920
Wilmington 1.647
Singapore 954
The Dalles 692
San Mateo 689
Dallas 542
Ann Arbor 530
Shanghai 522
Ashburn 465
Helsinki 437
Boardman 379
New York 338
Dublin 314
Leawood 310
Lawrence 288
Princeton 288
Benin City 271
Beijing 227
Hong Kong 174
Paris 153
Woodbridge 136
Fairfield 132
Amsterdam 108
São Paulo 101
Toronto 93
Milan 91
Seattle 74
Ho Chi Minh City 71
London 64
Los Angeles 62
Columbus 53
Council Bluffs 51
San Diego 49
Hanoi 48
Santa Clara 46
Brussels 42
Kocaeli 39
Rio de Janeiro 39
Norwalk 33
Moscow 29
Phoenix 28
Falls Church 27
Curitiba 24
Pune 24
Belo Horizonte 23
Warsaw 22
Falkenstein 20
Houston 20
Naples 20
Brooklyn 19
Frankfurt am Main 19
Brasília 18
San Jose 18
Porto Alegre 17
Orem 16
Stockholm 16
Tokyo 16
Boston 15
Cambridge 15
Campinas 15
Monmouth Junction 15
Rome 15
San Francisco 15
Atlanta 13
Munich 13
Salvador 13
Tashkent 13
Fortaleza 12
Mexico City 12
Montreal 12
Poplar 12
Asyut 11
Des Moines 11
Recife 11
Redmond 11
Redwood City 11
Andover 10
Chennai 10
Clearwater 10
Denver 10
São José dos Campos 10
Baghdad 9
Betim 9
Brno 9
Nairobi 9
Seoul 9
Skopje 9
Amman 8
Assago 8
Bauru 8
Buenos Aires 8
Chicago 8
Dhaka 8
Guarulhos 8
Las Vegas 8
Manchester 8
Reston 8
Ribeirão Preto 8
Sorocaba 8
Charlotte 7
Totale 13.300
Salva come PNG Salva come JPEG
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 184
12 weeks ombitasvir/paritaprevir-ritonavir plus ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis 130
A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. 121
Allelic inhibition of displacement activity: A simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms 116
Lack of Correlation Between Serum Anti-HBcore Detectability and Hepatocellular Carcinoma in Patients With HCV-Related Cirrhosis 114
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 110
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 106
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 104
Acute tubular necrosis following interferon-based therapy for hepatitis C : case study with literature review 102
Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C 101
A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019 100
Age Might Confound the Impact of the Transmembrane 6 Superfamily Member 2 E167K Polymorphism on Hepatic Fibrosis in Hepatitis C Virus-Infected Patients REPLY 97
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naive patients with genotype 1 chronic hepatitis C 96
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 96
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: Effects on blood pressure control and mortality 96
Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection 95
Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: Case study 94
A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? 93
A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis 92
Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 92
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 91
Pegylated IFN-alpha 2a and ribavirin in the treatment of hepatitis C 90
A Review of the Treatment of Chronic Hepatitis C Virus Infection in Cirrhosis 89
From current status to optimization of HCV treatment: Recommendations from an expert panel 89
Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives 88
Hepatocellular carcinoma in chronic hepatitis C: from bench to bedside 88
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 88
Real life experiences in HCV management in 2018 88
Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials 88
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection 86
Daclatasvir : a team player rather than a prima donna in the treatment of hepatitis C 85
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population 85
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 85
Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: The plot thickens 84
Assessing long-term treatment efficacy in chronic hepatitis B and C : Between evidence and common sense 84
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 84
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management 83
Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis 83
EASL Recommendations on Treatment of Hepatitis C 2014 82
Optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis C : more questions than answers 82
Deciding on interferon-free treatment for chronic hepatitis C : Updating liver stiffness cut-off values to maximize benefit 82
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission 82
A risk score based on baseline risk factors for predicting mortality in COVID-19 patients 82
High mortality in COVID-19 patients with mild respiratory disease 81
Impaired response to interferon-alpha 2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection 80
High levels of factor VIII and risk of extra-hepatic portal vein obstruction 80
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 80
The role of hepatic venous pressure gradient in hepatitis C virus compensated cirrhosis 79
The prevalence, clinical features and response to antiviral therapy of patients with chronic hepatitis C who are seropositive for liver-kidney microsome type 1 antibodies 79
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 79
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C 79
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent 78
COINCIDENCE OF CALCITONIN-GENE-RELATED PEPTIDE IMMUNOREACTIVITY AND TERMINAL FIELDS OF EFFERENTS FROM THE CARDIOVASCULAR PORTION OF THE FASTIGIAL NUCLEUS - PRELIMINARY-REPORT 78
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 78
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis 77
Daclatasvir for the treatment of chronic hepatitis C 77
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? 77
Are We Ready to Discontinue Hepatitis B Immunoglobulins to Prevent Hepatitis B and D Recurrence in Liver Transplant Recipients? 77
REGULATION OF VASOPRESSIN SECRETION AFTER ADMINISTRATION OF SODIUM-NITROPRUSSIDE IN HYPERTENSIVES 76
Interaction between PNPLA3 I148M variant and age at infection in determining fibrosis progression in chronic hepatitis C 76
Interferon-ribavirin therapy induces serum antibodies determining 'rods and rings' pattern in hepatitis C patients 76
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 76
Interferon in the treatment of chronic hepatitis C: a drug caught between past and future 75
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 75
The clinical impact of a 24-week treatment course of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia 75
Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection 75
OSMOREGULATION OF VASOPRESSIN DURING ACUTE LOWERING OF ARTERIAL-PRESSURE BY CLONIDINE IN MODERATE HYPERTENSION 75
Mapping the human genetic architecture of COVID-19 75
Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better 74
Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection 74
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review) 74
Critical Care Outreach Team During COVID-19: Ventilatory Support in the Ward and Outcomes 74
Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients 74
HCV genotype 3: An independent predictor of fibrosis progression in chronic hepatitis C 73
Low risk of hepatitis B reactivation in patients with chronic hepatitis C and concurrent inactive hepatitis B infection treated with interferon and ribavirin 73
Lack of rapid virological response. predicts interferon-alpha 2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study 73
Prevalence and Clinical Impact of Hepatitis E Virus in Immunosuppressed Patient after Liver Transplantation 73
Individualized hepatocellular carcinoma risk : the challenges for designing successful chemoprevention strategies 72
Chronic hepatitis C: standard of care and perspective 72
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection 72
Safety of vedolizumab in liver transplant recipients: A systematic review 72
Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? 71
Hepatorenal Syndrome and Novel Advances in its Management 71
Role of liver biopsy in hepatocellular carcinoma 71
Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage 70
Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis 70
TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma 70
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1 70
Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) 70
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication? 70
An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study 69
Diagnosis of hepatocellular carcinoma in cirrhosis by dynamic contrast imaging: The importance of tumor cell differentiation 69
Treatment of chronic hepatitis C: can complexity pave the way towards elimination? 69
Will the benefits of treatment for chronic hepatitis C be retained in the interferon-free era? 69
Hepatitis C treatment in patients with kidney disease 69
Ribavirin impairs salivary gland function in hepatitis C patients during combination treatment with pegylated interferon alfa-2a 68
Estimating HCV disease burden - volume 3 (editorial) 68
The Role Of Serum Alphafetoprotein Determination In HCV-Cirrhosis After Antiviral Treatment 68
Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon 68
Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response 68
Totale 8.308
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.742
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.969 0 0 0 0 0 964 481 213 528 399 13 371
2021/20221.691 79 18 59 359 20 21 77 221 121 197 405 114
2022/20234.749 675 211 459 563 430 409 7 418 877 362 273 65
2023/20242.682 184 263 549 130 103 422 149 153 38 46 250 395
2024/20253.997 118 102 51 88 96 417 286 500 551 906 459 423
2025/20264.066 1.484 628 640 876 225 213 0 0 0 0 0 0
Totale 20.268